SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Technology Stocks : Ariba Technologies (Nasdaq-ARBA) -- Ignore unavailable to you. Want to Upgrade?


To: Michael Auth who wrote (1407)11/15/2000 10:13:12 AM
From: 10K a day  Read Replies (1) | Respond to of 2110
 
OK Johnny! Just don't ARBA on yourself ....



To: Michael Auth who wrote (1407)11/16/2000 11:46:09 AM
From: Spytrdr  Read Replies (2) | Respond to of 2110
 
relax johnny, it "only" has to go to $ 118...

hahahahahahah

that's only $ 8 more billion added to its market cap from current levels.

hahahahahaha

annual sales: $ 279 million
ebitda: - $ 100 million
income available to common: - $ 792.8 million
total cash: $ 280 million

and its software doesn't even work...

"These problems can be lumped into two big buckets. First, Ariba has failed to live up to the technology promises it made to CoNext, frustrating customers who have not had their expectations met. Second, the b-to-b market has changed considerably since CoNext was announced in January, leaving it vulnerable to obsolescence.
The problems with Ariba center around its Internet procurement application -- the heart of CoNext's technology platform -- which reportedly could not handle the complexities of group buying, especially on the scale required by Fortune 500 companies with multibillion-dollar budgets, according to a recent report written by analyst Pierre Mitchell of AMR Research, which detailed CoNext's woes.
Ariba made a great deal of noise about supporting CoNext ... yet without strong technology support, [corporate customers] didn't deeply support the consortium, leaving it plagued by many problems," Mitchell writes in his report."

upside.com